Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBITDA: 2019-2024

Historic EBITDA for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to -$224.8 million.

  • Kymera Therapeutics' EBITDA fell 38.48% to -$81.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$295.6 million, marking a year-over-year decrease of 81.22%. This contributed to the annual value of -$224.8 million for FY2024, which is 57.68% down from last year.
  • According to the latest figures from FY2024, Kymera Therapeutics' EBITDA is -$224.8 million, which was down 57.68% from -$142.6 million recorded in FY2023.
  • In the past 5 years, Kymera Therapeutics' EBITDA registered a high of -$45.7 million during FY2020, and its lowest value of -$224.8 million during FY2024.
  • Over the past 3 years, Kymera Therapeutics' median EBITDA value was -$159.1 million (recorded in 2022), while the average stood at -$175.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 120.33% in 2021, then increased by 10.39% in 2023.
  • Kymera Therapeutics' EBITDA (Yearly) stood at -$45.7 million in 2020, then crashed by 120.33% to -$100.7 million in 2021, then plummeted by 57.91% to -$159.1 million in 2022, then climbed by 10.39% to -$142.6 million in 2023, then crashed by 57.68% to -$224.8 million in 2024.